Family Heart Foundation/X
Aug 26, 2025, 09:45
FDA Expands Repatha (Evolocumab) Approval: New Options for Adults With Uncontrolled LDL-C and HoFH
Family Heart Foundation posted on X:
”FDA expands approval of Repatha® (evolocumab) for adults at risk of CV events from uncontrolled LDL-C—even without established CVD. Now approved as monotherapy for HoFH. Important update for clinicians managing FH patients.”
Find more information here.
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 22:46Luke McLaughlin: Is Haemophilia a disability? – Vote or Share
-
Apr 23, 2026, 22:44Sonia Wolf: On My Way Back From a Very Invigorating BSH
-
Apr 23, 2026, 22:43Maximo Agustin Schiavone: ‘The Lower the Better’ Is Not a Physiological Principle
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:18Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care